Drugs by condition
Drugs approved for pancreatic cancer
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
20
Still marketed, NDA or BLA
Drug classes
5
Novel drugs
6
New molecular entities and new biologics
In development
40+
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for pancreatic cancer.
- Omcazio (Cabozantinib Laurylsulfate) · Handa Oncol Sep 3, 2026
- Rasonque (Daraxonrasib) · Revolution Medicines NovelPriority reviewOrphanAug 26, 2026
- Favlyxa (Fluorouracil) · Avyxa Holdings Feb 20, 2026
- Avgemsi (Gemcitabine Hydrochloride) · Avyxa Holdings Jun 27, 2025
- Bizengri (Zenocutuzumab-Zbco) · Merus N.V. NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanDec 4, 2024
All approved drugs for pancreatic cancer, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 50 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Kinase Inhibitor (2)
- Afinitor Everolimus · Novartis · 2009
- Afinitor Disperz Everolimus · Novartis Pharm · 2012
Cholecystokinin Analog (2)
Nucleoside Metabolic Inhibitor (1)
- Favlyxa Fluorouracil · Avyxa Holdings · 2026
Poly(ADP-Ribose) Polymerase Inhibitor (1)
- Lynparza Olaparib · Astrazeneca · 2017
Class not listed in FDA's data (14)
- Rasonque Daraxonrasib · Revolution Medicines · 2026
- Bizengri Zenocutuzumab-Zbco · Merus N.V. · 2024
- Sutent Sunitinib Malate · Cppi Cv · 2006
- Chirhostim Secretin Synthetic Human · Chirhoclin · 2004
- Omcazio Cabozantinib Laurylsulfate · Handa Oncol · 2026
- Avgemsi Gemcitabine Hydrochloride · Avyxa Holdings · 2025
- Cabometyx Cabozantinib S-Malate · Exelixis INC · 2016
- Onivyde Irinotecan Hydrochloride · Ipsen · 2015
- Pertzye Pancrelipase (Amylase, Lipase, Protease) · Digestive Care INC · 2012
- Viokace Pancrelipase (Amylase, Lipase, Protease) · Viokace · 2012
- Gemcitabine Hydrochloride Gemcitabine Hydrochloride · Hospira INC · 2011
- Pancreaze Pancrelipase (Amylase, Lipase, Protease) · Vivus INC · 2010
- Zenpep Pancrelipase (Amylase, Lipase, Protease) · Eurand Pharma LTD · 2009
- Creon Pancrelipase (Amylase, Lipase, Protease) · Abbvie · 2009
Drugs in development for pancreatic cancer
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- LM-108Phase 36 trials
LaNova Medicines Limited · Advanced Solid Tumor, Advanced Pancreatic Cancer, Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
- QLS31905Phase 35 trials
Qilu Pharmaceutical Co., Ltd. · Advanced Solid Tumor, CLDN18.2-positive Advanced Biliary Tract Cancer, Gastric Adenocarcinoma
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
1 discontinued brand-name drugs whose label still names it
- Xeloda Capecitabine
More on pancreatic cancer: recruiting trials · published research
Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.